Breast cancer, triple negative

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Section editor
Gayathri Nagaraj, MD
Loma Linda University
Loma Linda, CA, USA
LinkedIn

For placebo or observational studies in this condition, please visit this page.
Note: this page has regimens which are specific to breast cancer that is triple negative. Please see the breast cancer page for other chemotherapy regimens.

Last updated on 2024-09-06:
51 regimens on this page
69 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO


NCCN


St Gallen Breast Guidelines


Neoadjuvant therapy, sequential regimens

CP-AC

CP-AC: Carboplatin & Paclitaxel, followed by Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen variant #1, q3wk carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Abraham et al. 2024 (PARTNER) 2016-09 to 2021-12 Phase 3 (C) CP-AC & Olaparib Did not meet primary endpoint of pCR rate
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (C) 1a. CP-AC & Pembrolizumab
1b. CP-EC & Pembrolizumab 		Inferior EFS1

1Reported efficacy is based on the 2022 update.
Note: the anthracycline portion of the PARTNER trial was not described in Abraham et al. 2024; this is the dosing described for the CP portion.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, AC portion (cycles 5 to 8)

21-day cycle for 8 cycles (CP x 4; AC x 4)

Subsequent treatment


Regimen variant #2, weekly carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (C) 1a. CP-AC & Pembrolizumab
1b. CP-EC & Pembrolizumab 		Inferior EFS1

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, AC portion (cycles 5 to 8)

21-day cycle for 8 cycles (CP x 4; AC x 4)

Subsequent treatment

References

  1. KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03036488
    1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed
  2. PARTNER: Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra A, Qian W, Vallier AL, Hardy RM, Chan S, Hickish T, Tripathi D, Venkitaraman R, Persic M, Aslam S, Glassman D, Raj S, Borley A, Braybrooke JP, Sutherland S, Staples E, Scott LC, Davies M, Palmer CA, Moody M, Churn MJ, Newby JC, Mukesh MB, Chakrabarti A, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Tischkowitz M, Provenzano E, Earl HM. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024 May;629(8014):1142-1148. Epub 2024 Apr 8. link to original article link to PMC article contains partial protocol in manuscript PubMed NCT03150576


CP-ddAC

CP-ddAC: Carboplatin & Paclitaxel followed by dose-dense Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Sikov et al. 2014 (CALGB 40603) 2009-2012 Phase 3 (E-esc) 1. T-ddAC Superior pCR rate (primary endpoint)
2. T-ddAC & Bevacizumab
3. CP-ddAC & Bevacizumab 		Not reported

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, ddAC portion (cycles 5 to 8)

Supportive therapy, ddAC portion (cycles 5 to 8)

21-day cycle for 4 cycles, then 14-day cycle for 4 cycles (CP x 4; ddAC x 4)

Subsequent treatment

References

  1. CALGB 40603: Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. Epub 2014 Aug 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00861705


CP-AC & Pembrolizumab

CP-AC & Pembrolizumab: Carboplatin, Paclitaxel, Pembrolizumab, followed by Adriamycin (Doxorubicin), Cyclophosphamide, Pembrolizumab

Regimen variant #1, q3wk carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (E-RT-esc) 1a. CP-AC
1b. CP-EC 		Superior EFS1 (co-primary endpoint)
EFS36: 84.5% vs 76.8%
(HR 0.63, 95% CI 0.48-0.82)

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, AC portion (cycles 5 to 8)

Immunotherapy, both portions (cycles 1 to 8)

21-day cycle for 8 cycles (CP x 4; AC x 4)

Subsequent treatment


Regimen variant #2, weekly carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (E-RT-esc) 1a. CP-AC
1b. CP-EC 		Superior EFS1 (co-primary endpoint)
EFS36: 84.5% vs 76.8%
(HR 0.63, 95% CI 0.48-0.82)

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, AC portion (cycles 5 to 8)

Immunotherapy, both portions (cycles 1 to 8)

21-day cycle for 8 cycles (CP x 4; AC x 4)

Subsequent treatment

References

  1. KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03036488
    1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed


CP-EC

CP-EC: Carboplatin & Paclitaxel, followed by Epirubicin & Cyclophosphamide

Regimen variant #1, q3wk carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (C) 1a. CP-AC & Pembrolizumab
1b. CP-EC & Pembrolizumab 		Inferior EFS1

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, EC portion (cycles 5 to 8)

21-day cycle for 8 cycles (CP x 4; EC x 4)

Subsequent treatment


Regimen variant #2, weekly carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (C) 1a. CP-AC & Pembrolizumab
1b. CP-EC & Pembrolizumab 		Inferior EFS1

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, EC portion (cycles 5 to 8)

21-day cycle for 8 cycles (CP x 4; EC x 4)

Subsequent treatment

References

  1. KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03036488
    1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed


CP-EC & Pembrolizumab

CP-EC & Pembrolizumab: Carboplatin, Paclitaxel, Pembrolizumab, followed by Epirubicin, Cyclophosphamide, Pembrolizumab

Regimen variant #1, q3wk carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (E-RT-esc) 1a. CP-AC
1b. CP-EC 		Superior EFS1 (co-primary endpoint)
EFS36: 84.5% vs 76.8%
(HR 0.63, 95% CI 0.48-0.82)

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, EC portion (cycles 5 to 8)

Immunotherapy, both portions (cycles 1 to 8)

21-day cycle for 8 cycles (CP x 4; EC x 4)

Subsequent treatment


Regimen variant #2, weekly carboplatin

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (E-RT-esc) 1a. CP-AC
1b. CP-EC 		Superior EFS1 (co-primary endpoint)
EFS36: 84.5% vs 76.8%
(HR 0.63, 95% CI 0.48-0.82)

1Reported efficacy is based on the 2022 update.

Chemotherapy, CP portion (cycles 1 to 4)

Chemotherapy, EC portion (cycles 5 to 8)

Immunotherapy, both portions (cycles 1 to 8)

21-day cycle for 8 cycles (CP x 4; EC x 4)

Subsequent treatment

References

  1. KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03036488
    1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed


EC-D

EC-D: Epirubicin and Cyclophosphamide followed by Docetaxel

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
von Minckwitz et al. 2012 (GeparQuinto) 2007-2010 Phase 3 (C) EC-D & Bevacizumab Seems to have inferior pCR rate (primary endpoint)

Chemotherapy, EC portion (cycles 1 to 4)

Chemotherapy, D portion (cycles 5 to 8)

21-day cycle for 8 cycles (EC x 4; D x 4)

Subsequent treatment

References

  1. GeparQuinto: von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Group. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan 26;366(4):299-309. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00567554


EC-D & Bevacizumab

EC-D & Bevacizumab: Epirubicin and Cyclophosphamide followed by Docetaxel, with Bevacizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
von Minckwitz et al. 2012 (GeparQuinto) 2007-2010 Phase 3 (E-esc) EC-D Seems to have superior pCR rate (primary endpoint)

Chemotherapy, EC portion (cycles 1 to 4)

Chemotherapy, D portion (cycles 5 to 8)

Targeted therapy, all portions (cycles 1 to 8)

21-day cycle for 8 cycles (EC x 4; D x 4)

Subsequent treatment

References

  1. GeparQuinto: von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Group. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan 26;366(4):299-309. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00567554


nP-ddAC

nP-ddAC: nab-Paclitaxel followed by dose-dense Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Mittendorf et al. 2020 (IMpassion031) 2017-2019 Phase 3 (C) nP-ddAC & Atezolizumab Inferior pCR rate

Chemotherapy, nP portion (cycles 1 to 6)

Chemotherapy, ddAC portion (cycles 7 to 10)

Supportive therapy, ddAC portion (cycles 7 to 10)

14-day cycle for 10 cycles (nP x 6; ddAC x 4)

Subsequent treatment

References

  1. IMpassion031: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10;396(10257):1090-1100. Epub 2020 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03197935


nP-ddAC & Atezolizumab

nP-ddAC & Atezolizumab: nab-Paclitaxel followed by dose-dense Adriamycin (Doxorubicin) & Cyclophosphamide, with Atezolizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Mittendorf et al. 2020 (IMpassion031) 2017-2019 Phase 3 (E-esc) nP-ddAC Superior pCR rate (co-primary endpoint)

Chemotherapy, nP portion (cycles 1 to 6)

Chemotherapy, ddAC portion (cycles 7 to 10)

Supportive therapy, ddAC portion (cycles 7 to 10)

Immunotherapy, both portions (cycles 1 to 10)

14-day cycle for 10 cycles (nP x 6; ddAC x 4)

Subsequent treatment

References

  1. IMpassion031: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10;396(10257):1090-1100. Epub 2020 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03197935


T-AC

T-AC: Taxol (Paclitaxel) followed by Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Rugo et al. 2016 (I-SPY 2 veliparib) 2010-2012 Phase 3 (C) 1a. CP-AC & Veliparib
1b. CP-ddAC & Veliparib 		Inferior pCR rate (primary endpoint)
Loibl et al. 2018 (BrighTNess) 2014-2016 Phase 3 (C) 1a. CP-AC
1b. CP-ddAC 		Not reported
2a. CP-AC & Veliparib
2b. CP-ddAC & Veliparib 		Inferior pCR rate (primary endpoint)

Chemotherapy, T portion (cycles 1 to 12)

Chemotherapy, AC portion (cycles 13 to 16)

7-day cycle for 12 cycles, then 21-day cycle for 4 cycles (T x 12; AC x 4)

Subsequent treatment

References

  1. I-SPY 2 veliparib: Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016 Jul 7;375(1):23-34. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01042379
  2. BrighTNess: Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497-509. Epub 2018 Feb 28. link to original article contain protocol PubMed NCT02032277
    1. Update: Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 Apr;33(4):384-394. Epub 2022 Jan 31. link to original article PubMed


T-ddAC

T-ddAC: Taxol (Paclitaxel) followed by dose-dense Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Sikov et al. 2014 (CALGB 40603) 2009-2012 Phase 3 (C) 1. CP-ddAC
2. T-ddAC & Bevacizumab
3. CP-ddAC & Bevacizumab 		Inferior pCR rate (primary endpoint)
Rugo et al. 2016 (I-SPY 2 veliparib) 2010-2012 Phase 3 (C) 1a. CP-AC & Veliparib
1b. CP-ddAC & Veliparib 		Inferior pCR rate (primary endpoint)
Loibl et al. 2018 (BrighTNess) 2014-2016 Phase 3 (C) 1a. CP-AC
1b. CP-ddAC 		Not reported
2a. CP-AC & Veliparib
2b. CP-ddAC & Veliparib 		Inferior pCR rate (primary endpoint)

Chemotherapy, T portion (cycles 1 to 12)

Chemotherapy, ddAC portion (cycles 13 to 16)

Supportive therapy, ddAC portion (cycles 13 to 16)

7-day cycle for 12 cycles, then 14-day cycle for 4 cycles (T x 12; ddAC x 4)

Subsequent treatment

References

  1. CALGB 40603: Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. Epub 2014 Aug 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00861705
  2. I-SPY 2 veliparib: Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016 Jul 7;375(1):23-34. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01042379
  3. BrighTNess: Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497-509. Epub 2018 Feb 28. link to original article contain protocol PubMed NCT02032277
    1. Update: Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 Apr;33(4):384-394. Epub 2022 Jan 31. link to original article PubMed


Neoadjuvant chemotherapy

Carboplatin & Docetaxel

CbD: Carboplatin & Docetaxel

Regimen

Study Dates of enrollment Evidence Efficacy
Sharma et al. 2016 (GOMHGUGM022011) 2010-2015 Phase 2 56-59% pCR rate
Sharma et al. 2016 (PROGECT) 2011-2015 Phase 2 56-59% pCR rate

Note: Sharma et al. 2016 was a combined analysis of two separate clinical trials.

Chemotherapy

21-day cycle for 6 cycles

Subsequent treatment

References

  1. PROGECT: Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts. Clin Cancer Res. 2017 Feb 1;23(3):649-657. Epub 2016 Jun 14. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02302742
  2. GOMHGUGM022011: Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts. Clin Cancer Res. 2017 Feb 1;23(3):649-657. Epub 2016 Jun 14. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01560663
  3. CH-BC-007: NCT01150513


Carboplatin & Paclitaxel (CP)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Awaiting publication (PARTNER) 2016-09 to 2021-12 Phase 3 (C) CP & Olaparib TBD if different primary endpoint of pCR rate

Note: Dosing information is from CT.gov.

Chemotherapy

21-day cycle for 4 cycles

Subsequent treatment

References

  1. PARTNER: NCT03150576


Carboplatin & nab-Paclitaxel

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Gluz et al. 2018 (WSG-ADAPT-TN) 2013-2015 Phase 3 (E-switch-ic) Gemcitabine & nab-Paclitaxel Superior pCR rate (primary endpoint)

Chemotherapy

21-day cycle for 4 cycles

Subsequent treatment

References

  1. WSG-ADAPT-TN: Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N; West German Study Group. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01815242


Cisplatin monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Silver et al. 2010 (DFCI 04-183) 2004 to not reported Phase 2 50% good pathologic response

Chemotherapy

21-day cycle for 4 cycles

Subsequent treatment

References

  1. DFCI 04-183: Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1145-53. Epub 2010 Jan 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00148694


Cisplatin & Bevacizumab

Regimen

Study Dates of enrollment Evidence
Golshan et al. 2010 2006-11 to 2008-11 Phase 2

Chemotherapy

Targeted therapy

21-day cycle for 4 cycles

Subsequent treatment

References

  1. Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?. Ann Surg Oncol. 2011 Mar;18(3):733-7. Epub 2010 Sep 30. link to original article PubMed


Neoadjuvant response criteria

Clinical response rate (cRR)

Although fairly dated, some trials such as ACOSOG Z1031 make use of the WHO criteria for response to neoadjuvant therapy. Included here primarily for historical purposes.

References

  1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14. link to original article PubMed


Miller-Payne scoring system

  • Grade 1: No change or some changes to individual malignant cells, but no reduction in overall cellularity
  • Grade 2: Minor loss of tumor cells (up to 30%), but overall cellularity still high
  • Grade 3: An estimated 30 to 90% reduction in the number of tumor cells
  • Grade 4: Marked disappearance of tumor cells such that only small clusters or widely dispersed individual cells remain (loss of greater than 90% of tumor cells)
  • Grade 5: No invasive cancer cells identifiable in sections from the site of the tumor (carcinoma in situ may be present)

References

  1. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003 Oct;12(5):320-7. link to original article PubMed


Residual cancer burden (RCB)

  • The RCB is calculated as follows: RCB = 1.4 (finv*dprim)0.17 + [4(1 - 0.75LN)dmet]0.17
    • where dprim is derived from the bidimensional diameters of the primary tumor bed in the resected specimen, finv is the proportion of the primary tumor bed that contains invasive carcinoma, LN is the number of axillary lymph nodes containing metastatic carcinoma, and dmet is the diameter of the largest metastasis in an axillary lymph node.
    • The cut-off points are 1.36 and 3.28.

References

  1. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4. link to original article PubMed


Residual disease in breast and nodes (RDBN)

  • Level 1: pCR in breast and nodes with or without in situ carcinoma
  • Levels 2 to 4: Residual disease, calculated as 0.2 (residual breast tumor size in cm) + index of involved nodes (0 for no positive nodes, 1 for 1 to 4 positive nodes, 2 for 5 to 7 positive nodes, and 3 for 8 positive nodes) + the Scarff–Bloom–Richardson grade (1, 2, or 3). The cut-off points are 3 and 4.3.

References

  1. Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J. 2008 Mar-Apr;14(2):128-32. link to original article PubMed


Sataloff's classification

  • Breast:
    • T-A: Total or nearly total therapeutic effect
    • T-B: Greater than 50% therapeutic effect
    • T-C: Less than 50% therapeutic effect
    • T-D: No therapeutic effect
  • Lymph node:
    • N-A: Therapeutic effect but no metastasis
    • N-B: No metastasis, no therapeutic effect
    • N-C: Therapeutic effect but metastasis
    • N-D: Metastasis, no therapeutic effect

References

  1. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995 Mar;180(3):297-306. PubMed


Tumor response ratio

Calculated as follows: Residual breast disease observed upon pathologic examination divided by the size of the tumor on the pre-neoadjuvant therapy image.

  • TRR = 0: pathologic complete response (pCR)
  • TRR greater than 0 up to 0.4: strong partial response
  • TRR greater than 0.4 up to 1.0: weak partial response (WPR)
  • TRR greater than 1.0: tumor growth

References

  1. Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct;21(10):3317-23. Epub 2014 Jul 25. link to original article PubMed


ypTNM staging

This system is proprietary to the AJCC. Please visit their site or consult the AJCC Manual for further details.


Adjuvant therapy, sequential regimens

AC-T

AC-T: Adriamycin (Doxorubicin) & Cyclophosphamide followed by Taxol (Paclitaxel)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Yardley et al. 2017 (TITAN - breast) 2008-2011 Phase 3 (C) AC-Ixabepilone Did not meet primary endpoint of DFS
DFS60: 87.1% vs 84.7%
(HR 0.92)

Note: TITAN is labeled "TITAN - breast" so as not to confuse it with the trial by the same name in NSCLC.

Preceding treatment

Chemotherapy, AC portion (cycles 1 to 4)

Chemotherapy, T portion (cycles 5 to 16)

21-day cycle for 4 cycles, then 7-day cycle for 12 cycles (AC x 4; T x 12)

References

  1. TITAN - breast: Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017 Aug;164(3):649-658. Epub 2017 May 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00789581


D-FEC

D-FEC: Docetaxel followed by Fluorouracil, Epirubicin, Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Li et al. 2020 (CBCSG010) 2012-06 to 2013-12 Phase 3 (C) TX-CEX Seems to have inferior DFS

Preceding treatment

Chemotherapy, D portion (cycles 1 to 3)

Chemotherapy, FEC portion (cycles 4 to 6)

21-day cycle for 6 cycles (D x 3; FEC x 3)

References

  1. CBCSG010: Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Qu X, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Wang J, Zhang H, Wang S, Zhang J, Jin F, Rao N, Ma B, He P, Xu B, Zhuang Z, Wang J, Sun Q, Guo X, Mo M, Shao Z; CBCSG010 Study Group. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol. 2020 Jun 1;38(16):1774-1784. Epub 2020 Apr 10. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01642771


FEC-D

FEC-D: Fluorouracil, Epirubicin, Cyclophosphamide followed by Docetaxel
CEF-T: Cyclophosphamide, Epirubicin, Fluorouracil followed by Taxotere (Docetaxel)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Nasr et al. 2015 2008-2014 Phase 3 (C) FEC-CbD-CM Seems to have inferior OS
Yu et al. 2020 (PATTERN) 2011-2016 Phase 3 (C) CP Seems to have inferior DFS

Preceding treatment

Chemotherapy, FEC portion (cycles 1 to 3)

Chemotherapy, D portion (cycles 4 to 6)

21-day cycle for 6 cycles (FEC x 3; D x 3)

References

  1. Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015 Nov;3(19):284. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
  2. PATTERN: Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1390-1396. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01216111


TX-CEX

TX-CEX: Taxotere (Docetaxel) & Xeloda (Capecitabine) followed by Cyclophosphamide, Epirubicin, Xeloda (Capecitabine)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Li et al. 2020 (CBCSG010) 2012-06 to 2013-12 Phase 3 (E-esc) D-FEC Seems to have superior DFS (primary endpoint)
DFS60: 86.3% vs 80.4%
(HR 0.66, 95% CI 0.44-0.99)

Preceding treatment

Chemotherapy, TX portion (cycles 1 to 3)

Chemotherapy, CEX portion (cycles 4 to 6)

21-day cycle for 6 cycles (TX x 3; CEX x 3)

References

  1. CBCSG010: Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Qu X, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Wang J, Zhang H, Wang S, Zhang J, Jin F, Rao N, Ma B, He P, Xu B, Zhuang Z, Wang J, Sun Q, Guo X, Mo M, Shao Z; CBCSG010 Study Group. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol. 2020 Jun 1;38(16):1774-1784. Epub 2020 Apr 10. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01642771


T-ddAC

T-ddAC: Taxol (Paclitaxel) followed by dose-dense Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Awaiting publication (ALEXANDRA) 2018-ongoing Phase 3 (C) 1a. T-ddAC & Atezolizumab
1b. T-ddEC & Atezolizumab 		TBD if different primary endpoint of iDFS

Note: Dosing information is from ASCO 2021 Abstract TPS597.

Preceding treatment

Chemotherapy, T portion (cycles 1 to 12)

Chemotherapy, ddAC portion (cycles 13 to 16)

Supportive therapy, ddAC portion (cycles 13 to 16)

7-day cycle for 12 cycles, then 14-day cycle for 4 cycles (T x 12; ddAC x 4)

References

  1. ALEXANDRA: NCT03498716


T-ddEC

T-ddEC: Taxol (Paclitaxel) followed by dose-dense Epirubicin & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Awaiting publication (ALEXANDRA) 2018-ongoing Phase 3 (C) 1a. T-ddAC & Atezolizumab
1b. T-ddEC & Atezolizumab 		TBD if different primary endpoint of iDFS

Note: Dosing information is from ASCO 2021 Abstract TPS597.

Preceding treatment

Chemotherapy, T portion (cycles 1 to 12)

Chemotherapy, EC portion (cycles 13 to 16)

Supportive therapy, ddAC portion (cycles 13 to 16)

7-day cycle for 12 cycles, then 14-day cycle for 4 cycles (T x 12; EC x 4)

References

  1. ALEXANDRA: NCT03498716


Adjuvant chemotherapy

Cyclophosphamide & Doxorubicin (AC)

AC: Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1990 (NSABP B-15) 1984-1988 Phase 3 (E-RT-de-esc) 1. AC-CMF Did not meet co-primary endpoints of DFS/OS
2. CMF Did not meet co-primary endpoints of DFS/OS

Note: NSABP B-15 was conducted prior to routine testing of HER2, so it technically included "double-negative" patients. NSABP B-15 was one of the studies analyzed in the 1998 EBCTCG meta-analysis that supported FDA approval of doxorubicin for this indication.

Preceding treatment

Chemotherapy

21-day cycle for 4 cycles

References

  1. NSABP B-15: Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, Deutsch M. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990 Sep;8(9):1483-96. link to original article dosing details in manuscript have been reviewed by our editors PubMed
    1. Pooled update: Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. link to original article PubMed
  2. Meta-analysis: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42. link to original article PubMed


Bevacizumab-containing therapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cameron et al. 2013 (BEATRICE) 2007-2010 Phase 3 (E-esc) Standard adjuvant therapy Did not meet primary endpoint of IDFS
IDFS36: 83.7% vs 82.7%
(HR 0.87, 95% CI 0.72-1.07)

This is the negative experimental arm of an important negative trial, so is included here for historical reference purposes, only.

Preceding treatment

Chemotherapy

  • Standard chemotherapy (not specified)

Targeted therapy

References

  1. BEATRICE: Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013 Sep;14(10):933-42. Epub 2013 Aug 7. link to original article PubMed NCT00528567
    1. Update: Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017 Apr 1;28(4):754-760. link to original article PubMed


Capecitabine monotherapy

Regimen variant #1, 1300 mg/m2/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Wang et al. 2021 (SYSUCC-001) 2010-2016 Phase 3 (E-esc) Observation Superior DFS (primary endpoint)
DFS60: 82.8% vs 73%
(HR 0.64, 95% CI 0.42-0.95)

Note: this is a continuous (uninterrupted) dosing schema.

Preceding treatment

  • "Standard adjuvant therapy"

Chemotherapy

28-day cycle for 13 cycles (1 year)


Regimen variant #2, 2000 mg/m2/day x 6

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Mayer et al. 2021 (ECOG-ACRIN EA1131) 2015-2021 Phase 3 (C) 1a. Carboplatin
1b. Cisplatin 		Inconclusive whether non-inferior iDFS (primary endpoint)

Preceding treatment

Chemotherapy

21-day cycle for 6 cycles


Regimen variant #3, 2000 mg/m2/day x 8

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Lluch et al. 2019 (GEICAM/2003-11; CIBOMA/2004-01) 2006-2011 Phase 3 (E-esc) Observation Did not meet primary endpoint of DFS
DFS60: 79.6% vs 76.8%
(HR 0.82, 95% CI 0.63-1.06)

Chemotherapy

21-day cycle for 8 cycles


Regimen variant #4, 2500 mg/m2/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Masuda et al. 2017 (CREATE-X) 2007-2012 Phase 3 (E-esc) Standard therapy Superior DFS (primary endpoint)
DFS60: 74.1% vs 67.6%
(HR 0.70, 95% CI 0.53-0.92)

Superior OS (secondary endpoint)
OS60: 89.2% vs 83.6%
(HR 0.59, 95% CI 0.39-0.90)

Note: All patients in CREATE-X had residual disease at time of surgical resection. Although this trial was not specifically for TNBC, a large number (N=286) of enrolled patients had TNBC, and the survival benefit appeared limited to this group in the subgroup analysis.

Preceding treatment

  • Neoadjuvant chemotherapy containing anthracycline, taxane, or both, then surgery

Chemotherapy

21-day cycle for 6 to 8 cycles

References

  1. CREATE-X: Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M; Japan Breast Cancer Research Group; Korean Breast Cancer Study Group; Korean Cancer Study Group. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000000843
  2. GEICAM/2003-11; CIBOMA/2004-01: Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020 Jan 20;38(3):203-213. Epub 2019 Dec 5. Erratum in: J Clin Oncol. 2020 Mar 10;38(8):847. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00130533
  3. SYSUCC-001: Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021 Jan 5;325(1):50-58. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01112826
  4. ECOG-ACRIN EA1131: Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02445391
    1. PRO analysis: Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. link to original article link to PMC article PubMed
  5. SASCIA: NCT04595565


Carboplatin & Paclitaxel (CP)

PCb: Paclitaxel & Carboplatin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Yu et al. 2020 (PATTERN) 2011-2016 Phase 3 (E-esc) FEC-D Seems to have superior DFS (primary endpoint)
DFS60: 86.5% vs 80.3%
(HR 0.65, 95% CI 0.44-0.96)

Preceding treatment

Chemotherapy

28-day cycle for 6 cycles

References

  1. PATTERN: Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1390-1396. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01216111


CMF

CMF: Cyclophosphamide, Methotrexate, Fluorouracil

Regimen variant #1, 1000/50/2000

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Ploner et al. 2003 (ABCSG 3) 1984 to not reported Randomized (C) AV-CMF Did not meet endpoints of DFS/OS

Note: this trial was conducted prior to routine testing of HER2, so it technically included "double-negative" patients.

Preceding treatment

Chemotherapy

28-day cycle for 6 cycles


Regimen variant #2, 1400/80/1200

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Fisher et al. 1990 (NSABP B-15) 1984-1988 Phase 3 (C) 1. AC Did not meet co-primary endpoints of DFS/OS
2. AC-CMF Did not meet co-primary endpoints of DFS/OS

Note: this trial was conducted prior to routine testing of HER2, so it technically included "double-negative" patients.

Preceding treatment

Chemotherapy

28-day cycle for 6 cycles

References

  1. NSABP B-15: Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, Deutsch M. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990 Sep;8(9):1483-96. link to original article dosing details in manuscript have been reviewed by our editors PubMed
  2. ABCSG 3: Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; ABCSG. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie. 2003 Apr;26(2):115-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed


FAC

FAC: Fluorouracil, Adriamycin (Doxorubicin), Cyclophosphamide
CAF: Cyclophosphamide, Adriamycin (Doxorubicin), Fluorouracil

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Fetting et al. 1998 (INT-0108) 1989-1993 Phase 3 (C) FAC x 16 weeks Did not meet co-primary endpoints of RFS60/OS60

Note: this is referred to as the "Bull-Tormey CAF regimen".

Preceding treatment

Chemotherapy

21-day cycle for 6 cycles

References

  1. INT-0108: Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD; ECOG; CALGB. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul;16(7):2382-91. link to original article dosing details in manuscript have been reviewed by our editors PubMed


Pembrolizumab monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522) 2017-03 to 2018-09 Phase 3 (E-RT-esc) Placebo Superior EFS1 (co-primary endpoint)
EFS36: 84.5% vs 76.8%
(HR 0.63, 95% CI 0.48-0.82)

1Reported efficacy is based on the 2022 update.
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.

Preceding treatment

Immunotherapy

21-day cycle for up to 9 cycles

References

  1. KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03036488
    1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed


Metastatic disease, first-line therapy

Capecitabine & Docetaxel (TX)

TX: Taxotere (Docetaxel) & Xeloda (Capecitabine)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Fan et al. 2012 Not reported Phase 3 (C) DC Inferior ORR

Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

21-day cycle for up to 6 cycles

References

  1. Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013 May;24(5):1219-25. Epub 2012 Dec 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed


Carboplatin & Gemcitabine (GCb)

GCb: Gemcitabine & Carboplatin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
O'Shaughnessy et al. 2011 (TCD11485) 2007-2009 Randomized Phase 2 (C) GCb & Iniparib Inferior OS
O'Shaughnessy et al. 2014 (EFC11486) 2009-07 to 2010-03 Phase 3 (C) GCb & Iniparib Seems to have inferior PFS1
Median PFS: 4.1 vs 5.1 mo
(HR 1.27, 95% CI 1.02-1.54)
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (C) Investigator's choice of:
1a. GCb & Pembrolizumab
1b. Paclitaxel & Pembrolizumab
1c. nab-Paclitaxel & Pembrolizumab 		Inferior OS2

1This trial was declared negative by the authors due to splitting statistical power across two co-primary endpoints (PFS and OS).
2Reported efficacy for KEYNOTE-355 is based on the 2022 update and is for patients with CPS of 10 or more.
Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

21-day cycles

References

  1. TCD11485: O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011 Jan 20;364(3):205-14. Epub 2011 Jan 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00540358
  2. EFC11486: O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3840-7. Epub 2014 Oct 27. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00938652
  3. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed
  4. PRESERVE 2: EudraCT 2020-004930-39


Carboplatin & Gemcitabine (GCb) & Pembrolizumab

GCb & Pembrolizumab: Gemcitabine, Carboplatin, Pembrolizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (E-RT-esc) Investigator's choice of:
1a. GCb
1b. Paclitaxel
1c. nab-Paclitaxel 		Superior OS1 (co-primary endpoint)
Median OS: 23 vs 16.1 mo
(HR 0.73, 95% CI 0.55-0.95)

1Reported efficacy is based on the 2022 update and is in the group with CPS of 10 or more.

Chemotherapy

Immunotherapy

21-day cycle for up to 35 cycles (2 years)

References

  1. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed


Cisplatin & Docetaxel (DC)

TP: Taxotere (Docetaxel) & Platinol (Cisplatin)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Fan et al. 2012 Not reported Phase 3 (E-switch-ic) TX Superior ORR (primary endpoint)
ORR: 63% vs 15.4%

Superior OS (secondary endpoint)
Median OS: 32.8 vs 21.5 mo
(HR 0.41, 95% CI 0.18-0.92)

Chemotherapy

21-day cycle for up to 6 cycles

References

  1. Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013 May;24(5):1219-25. Epub 2012 Dec 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed


Cisplatin & Gemcitabine (GC)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Hu et al. 2015 (CBCSG006) 2011-2013 Phase 3 (E-switch-ic) Gemcitabine & Paclitaxel Superior PFS (primary endpoint)
Median PFS: 7.7 vs 6.5 mo
(HR 0.69, 95% CI 0.52-0.915)

Chemotherapy

21-day cycle for up to 8 cycles

References

  1. CBCSG006: Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):436-46. Epub 2015 Mar 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01287624


Docetaxel monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Tutt et al. 2018 (TNT) 2008-2014 Phase 3 (C) Carboplatin Did not meet primary endpoint of ORR

Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

21-day cycle for 6 to 8 cycles

References

  1. TNT: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00532727


FAC

FAC: Fluorouracil, Adriamycin (Doxorubicin), Cyclophosphamide

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Pandya et al. 2007 (ECOG E3185) 1987-1991 Phase 3 (C) CAF/TsAVbH Did not meet primary endpoint of TTF

Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

28-day cycle for up to 6 cycles

References

  1. ECOG E3185: Pandya KJ, Hu P, Osborne CK, Falkson G, Tormey DC; ECOG. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr;30(2):113-25. link to original article dosing details in manuscript have been reviewed by our editors PubMed


Gemcitabine & Paclitaxel

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Hu et al. 2015 (CBCSG006) 2011-2013 Phase 3 (C) GC Inferior PFS

Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

21-day cycle for up to 8 cycles

References

  1. CBCSG006: Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):436-46. Epub 2015 Mar 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01287624


Paclitaxel monotherapy

Regimen variant #1, 80 mg/m2

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Kim et al. 2017 (LOTUS) 2014-2016 Randomized Phase 2 (C) Ipatasertib & Paclitaxel Seems to have inferior PFS

Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

28-day cycles


Regimen variant #2, 90 mg/m2

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (C) Investigator's choice of:
1a. GCb & Pembrolizumab
1b. Paclitaxel & Pembrolizumab
1c. nab-Paclitaxel & Pembrolizumab 		Inferior OS1
Miles et al. 2021 (IMpassion131) 2017-2019 Phase 3 (C) Paclitaxel & Atezolizumab Did not meet primary endpoint of PFS
Median PFS: 5.7 vs 6 mo
(HR 1.22, 95% CI 0.89-1.67)

1Reported efficacy for KEYNOTE-355 is based on the 2022 update and is for patients with CPS of 10 or more.
Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

28-day cycles

References

  1. LOTUS: Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. Epub 2017 Aug 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02162719
  2. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed
  3. IMpassion131: Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994-1004. Epub 2021 Jul 1. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03125902


Paclitaxel & Pembrolizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (E-RT-esc) Investigator's choice of:
1a. Carboplatin & Gemcitabine
1b. Paclitaxel
1c. nab-Paclitaxel 		Superior OS1 (co-primary endpoint)
Median OS: 23 vs 16.1 mo
(HR 0.73, 95% CI 0.55-0.95)

1Reported efficacy is based on the 2022 update and is in the group with CPS of 10 or more.
Note: the duration of chemotherapy and immunotherapy cycles is different.

Chemotherapy

28-day cycles

Immunotherapy

21-day cycle for up to 35 cycles (2 years)

References

  1. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed


nab-Paclitaxel monotherapy

Regimen variant #1, 100 mg/m2 3 out of 4 weeks

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2018 (IMpassion130) 2015-2017 Phase 3 (C) nab-Paclitaxel & Atezolizumab Might have inferior OS
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (C) Investigator's choice of:
1a. GCb & Pembrolizumab
1b. Paclitaxel & Pembrolizumab
1c. nab-Paclitaxel & Pembrolizumab 		Inferior OS1

1Reported efficacy for KEYNOTE-355 is based on the 2022 update and is for patients with CPS of 10 or more.
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

28-day cycles


Regimen variant #2, 125 mg/m2 2 out of 3 weeks

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Jiang et al. (TORCHLIGHT) 2018-12-25 to 2022-11-30 Phase 3 (C) nab-Paclitaxel & Toripalimab Inferior PFS/OS

Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Chemotherapy

21-day cycle for up to 35 cycles (2 years)

References

  1. IMpassion130: Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. Epub 2018 Oct 20. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02425891
    1. Update: Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. Epub 2019 Nov 27. link to original article PubMed
    2. PRO analysis: Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 May;31(5):582-589. Epub 2020 Feb 20. link to original article PubMed
    3. Update: Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 Aug;32(8):983-993. Epub 2021 Jul 1. Erratum in: Ann Oncol. 2021 Aug 2;: Erratum in: Ann Oncol. 2021 Dec;32(12):1650. link to original article PubMed
  2. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed
  3. TORCHLIGHT: Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024 Jan;30(1):249-256. Epub 2024 Jan 8. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03777579


nab-Paclitaxel & Atezolizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schmid et al. 2018 (IMpassion130) 2015-2017 Phase 3 (E-RT-esc) nab-Paclitaxel Might have superior OS1 (co-primary endpoint)
Median OS: 21 vs 18.7 mo
(HR 0.87, 95% CI 0.75-1.02)

1Reported efficacy is based on the 2021 update.

Chemotherapy

Immunotherapy

28-day cycles

References

  1. IMpassion130: Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. Epub 2018 Oct 20. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02425891
    1. Update: Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. Epub 2019 Nov 27. link to original article PubMed
    2. PRO analysis: Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 May;31(5):582-589. Epub 2020 Feb 20. link to original article PubMed
    3. Update: Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 Aug;32(8):983-993. Epub 2021 Jul 1. Erratum in: Ann Oncol. 2021 Aug 2;: Erratum in: Ann Oncol. 2021 Dec;32(12):1650. link to original article PubMed


nab-Paclitaxel & Pembrolizumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cortes et al. 2020 (KEYNOTE-355) 2017-01-09 to 2018-06-12 Phase 3 (E-RT-esc) Investigator's choice of:
1a. Carboplatin & Gemcitabine
1b. Paclitaxel
1c. nab-Paclitaxel 		Superior OS1 (co-primary endpoint)
Median OS: 23 vs 16.1 mo
(HR 0.73, 95% CI 0.55-0.95)

1Reported efficacy is based on the 2022 update and is for patients with CPS of 10 or more.
Note: the duration of chemotherapy and immunotherapy cycles is different.

Chemotherapy

28-day cycles

Immunotherapy

21-day cycle for up to 35 cycles (2 years)

References

  1. KEYNOTE-355: Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-1828. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02819518
    1. Update: Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. link to original article PubMed


nab-Paclitaxel & Toripalimab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Jiang et al. (TORCHLIGHT) 2018-12-25 to 2022-11-30 Phase 3 (E-esc) nab-Paclitaxel Superior PFS (primary endpoint)
Median PFS: 8.4 vs 5.6 mo
(HR 0.65, 95% CI 0.47-0.91)

Superior OS (secondary endpoint)
Median OS: 32.8 vs 19.5 mo
(HR 0.62, 95% CI 0.41-0.91)

Chemotherapy

Immunotherapy

21-day cycle for up to 35 cycles (2 years)

References

  1. TORCHLIGHT: Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024 Jan;30(1):249-256. Epub 2024 Jan 8. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03777579


Metastatic disease, subsequent lines of therapy

Capecitabine monotherapy

Regimen variant #1, 2000 mg/m2/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Thomas et al. 2007 (CA163-046) 2003-2006 Phase 3 (C) Capecitabine & Ixabepilone Inferior PFS
Sparano et al. 2010 (CA163-048) 2003-2006 Phase 3 (C) Capecitabine & Ixabepilone Inferior PFS
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS
Dent et al. 2024 (IMpassion132) 2018-01-11 to 2023-08-04 Phase 3 (C) 1a. GCb & Atezolizumab
1b. Capecitabine & Atezolizumab 		Did not meet primary endpoint of OS
Median OS: 11.2 vs 12.1 mo
(HR 1.08, 95% CI 0.83-1.37)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: 25% of the patients in CA163-046 had TNBC. KEYNOTE-119 did not specify capecitabine dosing, which was left to the local standard of care. This is the lower bound of dosing specified in ASCENT.

Prior treatment criteria

  • CA163-046 & CA163-048: Exposure to anthracyclines and taxanes
  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy
  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

21-day cycles


Regimen variant #2, 2500 mg/m2/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

Note: This is the upper bound of dosing specified in ASCENT.

Prior treatment criteria

  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

21-day cycles

References

  1. CA163-046: Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. Epub 2007 Oct 29. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00080301
    1. Update: Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. Epub 2010 May 8. link to original article PubMed
    2. Pooled subgroup analysis: Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer. 2018 Dec;18(6):489-497. Epub 2018 Aug 4. link to original article PubMed
  2. CA163-048: Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63. Epub 2010 Jun 7. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00082433
    1. Pooled subgroup analysis: Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer. 2018 Dec;18(6):489-497. Epub 2018 Aug 4. link to original article PubMed
  3. KEYNOTE-119: Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499-511. Epub 2021 Mar 4. link to original article does not contain dosing details PubMed NCT02555657
  4. ASCENT: Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02574455
    1. Update: Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. Epub 2024 Feb 29. link to original article link to PMC article PubMed
  5. IMpassion132: Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024 Jul;35(7):630-642. Epub 2024 May 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03371017


Capecitabine & Ixabepilone

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Thomas et al. 2007 (CA163-046) 2003-2006 Phase 3 (E-esc) Capecitabine Superior PFS (primary endpoint)
Median PFS: 5.8 vs 4.2 mo
(HR 0.75, 95% CI 0.64-0.88)
Sparano et al. 2010 (CA163-048) 2003-2006 Phase 3 (E-esc) Capecitabine Might have superior OS (primary endpoint)
Median OS: 16.4 vs 15.6 mo
(HR 0.90, 95% CI 0.78-1.03)

Note: 25% of the patients in CA163-046 had TNBC.

Prior treatment criteria

  • CA163-046 & CA163-048: Exposure to anthracyclines and taxanes

Chemotherapy

21-day cycles

References

  1. CA163-046: Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. Epub 2007 Oct 29. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00080301
    1. Update: Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. Epub 2010 May 8. link to original article PubMed
    2. Pooled subgroup analysis: Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer. 2018 Dec;18(6):489-497. Epub 2018 Aug 4. link to original article PubMed
  2. CA163-048: Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63. Epub 2010 Jun 7. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00082433
    1. Pooled subgroup analysis: Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer. 2018 Dec;18(6):489-497. Epub 2018 Aug 4. link to original article PubMed


Carboplatin & Gemcitabine (GCb)

GCb: Gemcitabine & Carboplatin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
O'Shaughnessy et al. 2014 (EFC11486) 2009-07 to 2010-03 Phase 3 (C) GCb & Iniparib Seems to have inferior PFS1 (co-primary endpoint)
Median PFS: 4.1 vs 5.1 mo
(HR 1.27, 95% CI 1.02-1.54)
Dent et al. 2024 (IMpassion132) 2018-01-11 to 2023-08-04 Phase 3 (C) 1a. GCb & Atezolizumab
1b. Capecitabine & Atezolizumab 		Did not meet primary endpoint of OS
Median OS: 11.2 vs 12.1 mo
(HR 1.08, 95% CI 0.83-1.37)

1This trial was declared negative by the authors due to splitting statistical power across two co-primary endpoints (PFS and OS).

Chemotherapy

21-day cycles

References

  1. EFC11486: O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3840-7. Epub 2014 Oct 27. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00938652
  2. IMpassion132: Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024 Jul;35(7):630-642. Epub 2024 May 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT03371017


Enzalutamide monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Traina et al. 2018 (MDV3100-11) 2013-2014 Phase 2 CBR @ 16 wks: 25% (95% CI 17-33)

Biomarker eligibility criteria

  • AR-positive TNBC

Endocrine therapy

Continued indefinitely

References

  1. MDV3100-11: Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018 Mar 20;36(9):884-890. Epub 2018 Jan 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01889238


Eribulin monotherapy

Regimen variant #1, 1.23 mg/m2

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

Note: This is the European dosing in ASCENT.

Prior treatment criteria

  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

21-day cycles


Regimen variant #2, 1.4 mg/m2

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cortes et al. 2011 (EMBRACE) 2006-2008 Phase 3 (E-RT-switch-ic) Investigator's choice Seems to have superior OS (primary endpoint)
Median OS: 13.1 vs 10.6 mo
(HR 0.81, 95% CI 0.66-0.99)
Kaufman et al. 2015 (E7389-G000-301) 2006-2009 Phase 3 (E-switch-ic) Capecitabine Seems to have superior OS (co-primary endpoint)
Median OS: 15.9 vs 14.5 mo
(HR 0.88, 95% CI 0.77-1.00)
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: in EMBRACE, 144 patients (19%) had triple-negative breast cancer. In E7389-G000-301, 150 patients (24.5%) had triple-negative breast cancer. KEYNOTE-119 did not specify capecitabine dosing, which was left to the local standard of care. This is the North American dosing in ASCENT.

Prior treatment criteria

  • EMBRACE: Exposure to 2-5 prior lines of therapy, including an anthracycline and a taxane, unless contraindicated
  • E7389-G000-301: Exposure to anthracyclines and taxanes
  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy
  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

21-day cycles

References

  1. EMBRACE: Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. Epub 2011 Mar 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00388726
  2. E7389-G000-301: Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. Epub 2015 Jan 20. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00337103
  3. KEYNOTE-119: Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499-511. Epub 2021 Mar 4. link to original article does not contain dosing details PubMed NCT02555657
  4. ASCENT: Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02574455
    1. Update: Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. Epub 2024 Feb 29. link to original article link to PMC article PubMed


Gemcitabine monotherapy

Regimen variant #1, 800 mg/m2 3 weeks out of 4

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

Note: This is the lower bound of dosing specified by ASCENT.

Prior treatment criteria

  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

28-day cycles


Regimen variant #2, 1000 mg/m2 3 weeks out of 4

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: KEYNOTE-119 did not specify gemcitabine dosing, which was left to the local standard of care. This is a gemcitabine dosing schema used in recent phase 3 RCTs.

Prior treatment criteria

  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy

Chemotherapy

28-day cycles


Regimen variant #3, 1200 mg/m2 3 weeks out of 4

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

Note: This is the upper bound of dosing specified by ASCENT.

Prior treatment criteria

  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

28-day cycles


Regimen variant #4, 1250 mg/m2 2 weeks out of 3

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: KEYNOTE-119 did not specify gemcitabine dosing, which was left to the local standard of care. This is a gemcitabine dosing schema used in recent phase 3 RCTs.

Prior treatment criteria

  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy

Chemotherapy

21-day cycles

References

  1. KEYNOTE-119: Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499-511. Epub 2021 Mar 4. link to original article does not contain dosing details PubMed NCT02555657
  2. ASCENT: Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02574455
    1. Update: Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. Epub 2024 Feb 29. link to original article link to PMC article PubMed


Sacituzumab govitecan monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2017 (IMMU-132-01) 2013-2016 Phase 1/2 (RT)
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (E-RT-switch-ooc) Investigator's choice of:
1a. Capecitabine
1b. Eribulin
1c. Gemcitabine
1d. Vinorelbine 		Superior PFS1 (primary endpoint)
Median PFS: 4.8 vs 1.7 mo
(HR 0.41, 95% CI 0.33-0.52)

Superior OS1 (secondary endpoint)
Median OS: 11.8 vs 6.9 mo
(HR 0.51, 95% CI 0.42-0.63)

1Reported efficacy for ASCENT is based on the 2024 update.

Prior treatment criteria

  • IMMU-132-01: Exposure to at least one line of standard therapy
  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Antibody-drug conjugate therapy

21-day cycles

References

  1. IMMU-132-01: Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. Epub 2017 Mar 14. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01631552
    1. Update: Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 Feb 21;380(8):741-751. link to original article PubMed
  2. ASCENT: Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02574455
    1. Update: Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. Epub 2024 Feb 29. link to original article link to PMC article PubMed


Vinorelbine monotherapy

Regimen variant #1, 25 mg/m2 weekly

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bardia et al. 2021 (ASCENT) 2017-2019 Phase 3 (C) Sacituzumab govitecan Inferior OS

Prior treatment criteria

  • ASCENT: Exposure to taxanes and one additional line of standard therapy

Chemotherapy

21-day cycles


Regimen variant #2, 30 mg/m2 weekly

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: KEYNOTE-119 did not specify vinorelbine dosing, which was left to the local standard of care. This is a vinorelbine dosing schema used in recent phase 3 RCTs.

Prior treatment criteria

  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy

Chemotherapy

21-day cycles


Regimen variant #3, 30 mg/m2 q3wk

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: KEYNOTE-119 did not specify vinorelbine dosing, which was left to the local standard of care. This is a vinorelbine dosing schema used in recent phase 3 RCTs.

Prior treatment criteria

  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy

Chemotherapy

21-day cycles


Regimen variant #4, 30 mg/m2 2 out of 3 weeks

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winer et al. 2021 (KEYNOTE-119) 2015-2017 Phase 3 (C) Pembrolizumab Did not meet primary endpoint of OS1
Median OS: 10.8 vs 9.9 mo
(HR 1.03, 95% CI 0.87-1.22)

1Reported results are for the overall population. Statistical significance was not met for any of the three primary study populations.
Note: KEYNOTE-119 did not specify vinorelbine dosing, which was left to the local standard of care. This is a vinorelbine dosing schema used in recent phase 3 RCTs.

Prior treatment criteria

  • KEYNOTE-119: Exposure to anthracyclines or taxanes, with progression on most recent therapy

Chemotherapy

21-day cycles

References

  1. KEYNOTE-119: Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499-511. Epub 2021 Mar 4. link to original article does not contain dosing details PubMed NCT02555657
  2. ASCENT: Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02574455
    1. Update: Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. Epub 2024 Feb 29. link to original article link to PMC article PubMed


Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer,_triple_negative&oldid=94429"